panitumumab
amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'crcsm', 'improve ', 'panitumumab']
#asco2022 we just presented improve study results : intermittent folfiri/panitumumab in ras/braf wt unresectable mcrc showed a mpfs on treatment of 17.1 vs 13.2 (20.2 vs 13 in left sided) months vs standard continous exposure, with less skin related toxicities #crcsm 